ASPEN PHAR.UN.ADR /1 O.N. (LDZU) — Capital Reinvestment Ratio
Latest as of June 2025:
0.98x
ASPEN PHAR.UN.ADR /1 O.N. (LDZU) has a Capital Reinvestment Ratio of 0.98x as of June 2025, meaning it reinvests 1% of its operating cash flow (€5.16 Billion) in capital expenditures (€5.05 Billion). See LDZU free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.98x
Capex / Operating Cash Flow
Operating Cash Flow
€5.16 Billion
EUR
Capital Expenditures
€5.05 Billion
EUR
Data as of
Jun 2025
Most recent filing
ASPEN PHAR.UN.ADR /1 O.N. Capital Reinvestment Ratio (2022–2025)
This chart tracks ASPEN PHAR.UN.ADR /1 O.N.'s Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
Year-by-year Capital Reinvestment Ratio for ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025. For live market cap and broader valuation context, see ASPEN PHAR.UN.ADR /1 O.N. market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.98x | €5.16 Billion | €5.05 Billion | ▲ +10.2% |
| 2024 | 0.89x | €6.22 Billion | €5.54 Billion | ▲ +54.3% |
| 2023 | 0.58x | €5.52 Billion | €3.18 Billion | ▲ +14.8% |
| 2022 | 0.50x | €5.37 Billion | €2.70 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow